http://www.edisoninvestmentresearch.co.uk en Copyright 2012 2012-02-08 http://www.edisoninvestmentresearch.co.uk/research/category/tigenix Cells and marketing Edison Investment Research - ISIN: BE0003864817]]> 2012-02-06T12:32:57+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/ab-science Improving masitinib outlook Edison Investment Research - ISIN: FR0010557264 ]]> 2012-02-06T11:24:23+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/agennix-ag Sepsis trial stopped Edison Investment Research - ISIN: DE000A1A6XX4]]> 2012-02-03T15:11:14+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/magforce Nanomedicine player Edison Investment Research - ISIN: DE000A0HGQF5]]> 2012-02-03T12:05:49+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/sangamo-biosciences Genome editor Edison Investment Research - ISIN: US8006771062]]> 2012-02-03T11:52:53+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/prometic-life-sciences Revenue receipts roll in Edison Investment Research - ISIN: CA74342Q1046]]> 2012-02-03T09:06:43+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/algeta Flesh on the bones Edison Investment Research - ISIN: NO0010239437 ]]> 2012-02-02T14:53:57+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/orexo Unlocking Abstral’s value Edison Investment Research - ISIN: SE0000736415]]> 2012-02-01T16:16:01+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/curis Vismodegib approved Edison Investment Research - ISIN: US2312691015]]> 2012-01-31T15:41:49+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/SkyePharma Two hurdles to jump Edison Investment Research - ISIN: GB00B3BFNB64]]> 2012-01-31T14:37:42+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/infinity-pharmaceuticals Pancreatic setback Edison Investment Research - ISIN: US45665G3039]]> 2012-01-30T12:27:00+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/pharmaxis Now breathing easier Edison Investment Research - ]]> 2012-01-30T10:44:04+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/medigene Rapid facts expected Edison Investment Research - ISIN: DE0005020903]]> 2012-01-27T08:51:01+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/4sc Positive in SHELTER Edison Investment Research - ISIN: DE0005753818]]> 2012-01-24T14:20:30+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/ablynx The refined strategy Edison Investment Research - ISIN: BE0003877942]]> 2012-01-23T15:44:11+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/synta-pharmaceuticals Funds to expand studies Edison Investment Research - ISIN: US87162T2069]]> 2012-01-23T15:05:27+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/Phytopharm Backing for dual strategy Edison Investment Research - ISIN: GB0006869720]]> 2012-01-23T12:35:32+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/Deltex-Medical 2013 upside potential Edison Investment Research - ISIN: GB0059337583]]> 2012-01-17T14:16:22+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/transgene Coming of age Edison Investment Research - ISIN: FR0005175080]]> 2012-01-17T12:27:24+00:00 http://www.edisoninvestmentresearch.co.uk/research/category/hybrigenics Recruitment complete Edison Investment Research - ISIN: FR0004153930]]> 2012-01-17T09:43:14+00:00